

FW Receipt



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83533

Masakazu SATO, *et al.*

Appln. No.: 10/518,788

Group Art Unit: 1623

Confirmation No.: 9875

Examiner: Not Yet Assigned

Filed: December 13, 2004

For: ARYL 5-THIO- β -GLUCOPYRANOSIDE DERIVATIVES AND THERAPEUTIC AGENTS FOR DIABETES CONTAINING THE SAME

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following corrections:

Foreign Applications:

Japan 2002-233015 ~~09/08/2002~~ 08/09/2002

Title:

ARYL-5-THIO- β -~~BETA~~-D-GLUCOPYRANOSIDE DERIVATIVES AND ~~REMEDIES~~
~~FOR DIABETES CONTAINING THE SAME~~ THERAPEUTIC AGENTS FOR DIABETES
CONTAINING THE SAME

Request for Corrected Official Filing Receipt
U.S. Application No. 10/518,788


Q83533

The correct title should read: ARYL 5-THIO- β -GLUCOPYRANOSIDE DERIVATIVES
AND THERAPEUTIC AGENTS FOR DIABETES CONTAINING THE SAME

Verification for the requested corrections is indicated on the Declaration and Power of
Attorney filed December 21, 2004.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


Susan J. Mack
Registration No. 30,951

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 5, 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/518,788	12/21/2004	1623	2110	Q83533		18	7

CONFIRMATION NO. 9875

FILING RECEIPT



OC000000016180954

23373
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037

Ropes & Gray

JUN 15 2005

DOCKETED

JUN 21 2005

Intellectual Property Dept.

Date Mailed: 06/06/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Masakazu Sato, Tokyo, JAPAN; ✓
Hiroyuki Kakinuma, Tokyo, JAPAN; ✓
Hajime Asanuma, Tokyo, JAPAN; ✓

Assignment For Published Patent Application

Taisho Pharmaceutical Co., Ltd. ✓

Power of Attorney: The patent practitioners associated with Customer Number 23373. ✓

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/10160 08/08/2003 ✓

Foreign Applications

JAPAN 2002-233015 09/08/2002 08/09/2002
JAPAN 2003-97839 04/01/2003 ✓

Projected Publication Date: 09/08/2005

Non-Publication Request: No

Early Publication Request: No

Title

~~Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same~~

Preliminary Class

514

**ARYL 5-THIO-B-D-GLUCOPYRANOSIDE DERIVATIVES AND
THERAPEUTIC AGENTS FOR DIABETES CONTAINING THE SAME**

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).